Abstracts tagged "Biologic agents"

Abstract Number: 765 • 2016 ACR/ARHP Annual Meeting
High Baseline B Lymphocyte Stimulator (BLyS) Levels Predict Response While Smoking and Organ Damage at Baseline Predict Failure to Belimumab in Three Swedish Clinical Practice Settings
Ioannis Parodis¹, Christopher Sjöwall², Andreas Jönsen³, Agneta Zickert¹, Daniel Ramsköld¹, Martina Frodlund², Laurent Arnaud¹, Vivianne Malmström¹, Anders A. Bengtsson³ and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden
Background/Purpose: Belimumab is a biologic drug approved to treat Systemic Lupus Erythematosus (SLE). The efficacy of belimumab has been demonstrated in phase III clinical trials.…
Abstract Number: 1717 • 2016 ACR/ARHP Annual Meeting
Progression of Radiographic Axial Damage in Patients with Psoriatic Arthritis. Relation with Clinical and Analytical Factors
Alba Quesada-Moreno¹, Maria Dolores Sanchez-González², Laura Pérez-Garrido³, Ricardo Usategui-Martín⁴, Guadalupe Manzano-Canabal¹, Cristina Hidalgo-Calleja¹, Olga Martínez-González¹, Javier Del Pino-Montes¹ and Carlos Alberto Montilla-Morales¹, ¹Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ²HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, ³Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, SALAMANCA, Spain, ⁴IBSAL, SALAMANCA, Spain
Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is a controversial issue. Lack of unanimity in the definition has led to a wide range of…
Abstract Number: 2478 • 2016 ACR/ARHP Annual Meeting
Impact of Poor Prognostic Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Arthritis: Findings from a US Observational Cohort
LR Harrold¹, E Alemao², HJ Litman³, SE Connolly⁴, S Kelly², W Hua³, L Rosenblatt², S Rebello⁵ and JM Kremer⁶, ¹University of Massachusetts Medical School, Worcester, MA, ²Bristol-Myers Squibb, Princeton, NJ, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Poor prognostic factors can determine the extent of disease progression, disability and treatment outcomes in patients (pts) with RA. It is currently unknown whether…
Abstract Number: 2743 • 2016 ACR/ARHP Annual Meeting
Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
John Kelsall¹, Pauline Boulos², Regan Arendse³, Michelle Teo⁴, Anna Jaroszynska⁵, Michael Starr⁶, Alexander Tsoukas⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Karina Maslova¹⁰, Cathy Tkaczyk¹¹, Francois Nantel¹², Brendan Osborne¹¹ and Allen J Lehman¹⁰, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, McMaster University, Hamilton, ON, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁵Private practice, Burlington, ON, Canada, ⁶Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁷McGill University, Montreal, QC, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have shown associations between swelling or tenderness of specific joints in RA patients and patient pain. This analysis aimed to describe the…
Abstract Number: 770 • 2016 ACR/ARHP Annual Meeting
Introducing a Novel SLE-Specific IFN-I Inhibitor CNTO 6358: Laying the Groundwork for Precision Medicine in Lupus
Jarrat Jordan¹, Matteo Cesaroni¹, Jessica Schreiter¹, Chichi Huang², Tanesha Cash-Mason³, Marc Chevrier¹ and Jacqueline Benson¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Biologics Research, Janssen Research and Development, LLC., Spring House, PA, ³Cardiovascular and Metabolism Research, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: The type I interferon (IFN-I) family of cytokines signal through a ubiquitously expressed heterodimeric receptor (IFNAR) composed of IFNAR1 and the high-affinity binding chain…
Abstract Number: 1719 • 2016 ACR/ARHP Annual Meeting
Secular Trends in Treatment Patterns for Psoriasis and Psoriatic Arthritis: A Population-Based Cohort Study
Joseph F Merola¹, Joyce Lii², Rishi J. Desai³, Daniel H. Solomon⁴ and Seoyoung C. Kim⁵, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medicine, Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis (Pso) and psoriatic arthritis (PsA) are complex, multi-system diseases for which an ever-increasing landscape of therapies exists. Little is known about the population…
Abstract Number: 2491 • 2016 ACR/ARHP Annual Meeting
Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?
Pascal Zufferey¹, Melanie Favre dit Jeanfavre², Alexandre Dumusc³, Charles Benaim⁴, Matthieu Perreau⁵ and Alexander K. So Sr.⁶, ¹Rhu /Dal .Chuv, Rheumatology, Lausanne, Switzerland, ²DAL, RHU, Lausanne, Switzerland, ³DAL, RHU/CHUV, Lausanne, Switzerland, ⁴DAL, MPR, Lausanne, Switzerland, ⁵Medecine /CHUV, Immunology, Lausanne, Switzerland, ⁶Service De Rhumatologie, CHUV, Lausanne, Switzerland
Background/Purpose: All biologic agents (bDMARDs) currently used in rheumatology can induce anti-drug antibodies (ADAB), which will influence the drug levels and the drug effectiveness. Why…
Abstract Number: 2746 • 2016 ACR/ARHP Annual Meeting
Comparing Prevalence of Comorbidities in Patients with Psoriatic Arthritis By Biologic Therapy
Jeffrey Kaine¹, Xue Song², Gilwan Kim² and Jacqueline Palmer³, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Truven Health Analytics, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Psoriatic Arthritis (PsA) are known to be at higher risk for numerous comorbid conditions. This study looks at the impact of biologic therapy…
Abstract Number: 876 • 2016 ACR/ARHP Annual Meeting
Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Richard Conway¹, Lorraine O'Neill², Phil Gallagher³, Eileen O'Flynn⁴, Geraldine M. McCarthy⁵, Conor Murphy⁶, Douglas J. Veale⁷, Ursula Fearon⁸ and Eamonn S. Molloy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁵Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁶Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁷Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ⁸Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland, ⁹Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids with attendant significant adverse events. There is a critical need for alternative therapies. Interleukins…
Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
J. Antonio Avina-Zubieta¹, Andrew Chow², Philip Baer³, John Kelsall⁴, Proton Rahman⁵, Jacqueline Stewart⁶, Boulos Haraoui⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Francois Nantel¹¹, Karina Maslova¹², Cathy Tkaczyk¹³, Brendan Osborne¹³ and Allen J Lehman¹², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Independent Rheumatology Practice, Scarborough, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Montreal, Montreal, QC, Canada, ⁸Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
Abstract Number: 940 • 2016 ACR/ARHP Annual Meeting
A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
John H. Stone¹, Zachary S. Wallace², Cory A. Perugino³, Ana D. Fernandes⁴, Paul A. Foster⁵ and Debra J. Zack⁵, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Rheumatology Unit, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Xencor, Inc., San Diego, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can lead to irreversible damage. No approved therapies for IgG4-RD exist. We…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…

« Previous Page
1
…
8
9
10
11
12
…
26
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].